Developing an objective evaluating system to quantify the degree of upper limb movement impairment in patients with severe Friedreich's ataxia.
Friedreich’s ataxia
Quantitative measurements
SARA
Touchscreen application
Upper limb movement impairment
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
20
06
2019
accepted:
09
01
2020
pubmed:
30
1
2020
medline:
27
2
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
The use of standardized tools and objective measurements is essential to test the effectiveness of new drugs or rehabilitative protocols. Friedreich's ataxia (FRDA) patients with severe disease are often unable to perform the quantitative measurement tests currently used. The purpose of our study was to develop an easy-to-use application, for touchscreen devices, able to quantify the degree of upper limb movement impairment in patients with severe Friedreich's ataxia. The APP, which we named "Twelve-Red-Squares App-Coo-Test" (12-RSACT), assesses the upper limb ataxia by measuring the test execution time. All patients were clinically evaluated using the Composite Cerebellar Functional Severity (CCFS) and the Scale for the Assessment and Rating of Ataxia (SARA). We recruited 92 healthy subjects and 36 FRDA patients with a SARA mean value of 28.8.1 ± 8.2. All participants in our study underwent upper limb movement assessment using the new 12-RSACT, the Click Test, and a well-established system, i.e., the Nine-Hole Peg Test (9HPT). We observed a strong linear correlation between the measurements obtained with the 12-RSACT and those obtained with 9HPT, Click Test, CCFS, and SARA. The 12-RSACT was characterized by excellent internal consistency and intra-rater and test-retest reliability. The minimal detectable change (MDC%) was excellent too. Additionally, the 12-RSACT turned out to be faster and easier to perform compared with the 9HPT. The 12-RSACT is an inexpensive test and is easy to use, which can be administered quickly. Therefore, 12-RSACT is a promising tool to assess the upper limb ataxia in FRDA patients and even those with severe diseases.
Sections du résumé
BACKGROUND
BACKGROUND
The use of standardized tools and objective measurements is essential to test the effectiveness of new drugs or rehabilitative protocols. Friedreich's ataxia (FRDA) patients with severe disease are often unable to perform the quantitative measurement tests currently used.
AIM
OBJECTIVE
The purpose of our study was to develop an easy-to-use application, for touchscreen devices, able to quantify the degree of upper limb movement impairment in patients with severe Friedreich's ataxia. The APP, which we named "Twelve-Red-Squares App-Coo-Test" (12-RSACT), assesses the upper limb ataxia by measuring the test execution time.
METHODS
METHODS
All patients were clinically evaluated using the Composite Cerebellar Functional Severity (CCFS) and the Scale for the Assessment and Rating of Ataxia (SARA). We recruited 92 healthy subjects and 36 FRDA patients with a SARA mean value of 28.8.1 ± 8.2. All participants in our study underwent upper limb movement assessment using the new 12-RSACT, the Click Test, and a well-established system, i.e., the Nine-Hole Peg Test (9HPT).
RESULTS
RESULTS
We observed a strong linear correlation between the measurements obtained with the 12-RSACT and those obtained with 9HPT, Click Test, CCFS, and SARA. The 12-RSACT was characterized by excellent internal consistency and intra-rater and test-retest reliability. The minimal detectable change (MDC%) was excellent too. Additionally, the 12-RSACT turned out to be faster and easier to perform compared with the 9HPT.
CONCLUSION
CONCLUSIONS
The 12-RSACT is an inexpensive test and is easy to use, which can be administered quickly. Therefore, 12-RSACT is a promising tool to assess the upper limb ataxia in FRDA patients and even those with severe diseases.
Identifiants
pubmed: 31993871
doi: 10.1007/s10072-020-04249-0
pii: 10.1007/s10072-020-04249-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1587Références
Di Donato S, Gellera C, Mariotti C (2001) The complex clinical and genetic classification of inherited ataxias. II. Autosomal recessive ataxias. Neurol Sci 22(3):219–228
pubmed: 11731874
doi: 10.1007/s100720100017
Embiruçu EK, Martyn ML, Schlesinger D, Kok F (2009) Autosomal recessive ataxias: 20 types and counting. Arq Neuropsiquiatr 67:1143–1156
pubmed: 20069237
doi: 10.1590/S0004-282X2009000600036
Marcotulli C, Fortuni S, Arcuri G, Tomassini B, Leonardi L, Pierelli F, Testi R, Casali C (2016) GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients. Neurol Sci 37(3):361–364
pubmed: 26621361
doi: 10.1007/s10072-015-2427-3
Leonardi L, Aceto MG, Marcotulli C, Arcuria G, Serrao M, Pierelli F, Paone P, Filla A, Roca A, Casali C (2017) A wearable proprioceptive stabilizer for rehabilitation of limb and gait ataxia in hereditary cerebellar ataxias: a pilot open-labeled study. Neurol Sci 38(3):459–463
pubmed: 28039539
doi: 10.1007/s10072-016-2800-x
Pandolfo M, Pastore A (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol 256:9–17
pubmed: 19283345
doi: 10.1007/s00415-009-1003-2
Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, MacMillan JC, Collins V, Williamson R, Forrest SM (1999) Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 87:168–174
pubmed: 10533031
doi: 10.1002/(SICI)1096-8628(19991119)87:2<168::AID-AJMG8>3.0.CO;2-2
Delatycki MB, Knight M, Koenig M, Cossee M, Williamson R, Forrest SM (1999) G130V, a common FRDA point mutation appears to have arisen from a common founder. Hum Genet 105:343–346
pubmed: 10543403
doi: 10.1007/s004399900142
Cossée M, Dürr A, Schmitt M, Dahl N, Trouillas P, Allinson P et al (1999) Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45(2):200–206
pubmed: 9989622
doi: 10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U
Pelliccia V, Ferranti S, Mostardini R, Grosso S (2019) A case of Friedreich ataxia in an adolescent with 16p11.2 microdeletion syndrome. Neurol Sci. https://doi.org/10.1007/s10072-019-04075-z
Daiou C, Christodoulou K, Xiromerisiou G, Panas M, Dardiotis E, Kladi A, Speletas M, Ntaios G, Papadimitriou A, Germenis A, Hadjigeorgiou GM (2010) Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene. Neurol Sci 31(3):393–397
pubmed: 19953284
doi: 10.1007/s10072-009-0201-0
Federico A (2004) Ataxia with isolated vitamin E deficiency: a treatable neurologic disorder resembling Friedreich’s ataxia. Neurol Sci 25(3):119–121
pubmed: 15300458
doi: 10.1007/s10072-004-0245-0
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271(5254):1423–1427
pubmed: 8596916
doi: 10.1126/science.271.5254.1423
Heidari MM, Houshmand M, Hosseinkhani S, Nafissi S, Scheiber-Mojdehkar B, Khatami M (2008) Association between trinucleotide CAG repeats of the DNA polymerase gene (POLG) with age of onset of Iranian Friedreich’s ataxia patients. Neurol Sci 29(6):489–493
pubmed: 19043662
doi: 10.1007/s10072-008-1026-y
Christodoulou K, Deymeer F, Serdaroğlu P, Özdemir C, Poda M, Georgiou DM et al (2001) Mapping of the second Friedreich’s ataxia (FRDA2) locus to chromosome 9p23-p11: evidence for further locus heterogeneity. Neurogenetics 3(3):127–132
pubmed: 11523563
doi: 10.1007/s100480100112
Rajesh S et al (2002) The GAA triplet-repeat sequence in Friedreich ataxia shows a high level of somatic instability in vivo, with a significant predilection for large contractions. Hum Mol Genet 11(18):2175–2187
doi: 10.1093/hmg/11.18.2175
Sharma R, De Biase I, Gomez M, Delatycki MB, Ashizawa T, Bidichandani SI (2004) Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann Neurol 56:898–901
pubmed: 15562408
doi: 10.1002/ana.20333
Santos R, Lefevre S, Sliwa S, Seguin A, Camadro J, Lesuisse E (2010) Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 13:651–690
pubmed: 20156111
pmcid: 2924788
doi: 10.1089/ars.2009.3015
Bulteau AL, Dancis A, Gareil M, Montagne JJ, Camadro JM, Lesuisse E (2007) Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42:1561–1570
pubmed: 17448903
doi: 10.1016/j.freeradbiomed.2007.02.014
Clemm von Hohenberg C, Schocke MF, Wigand MC, Nachbauer W, Guttmann CR, Kubicki M, Shenton ME, Boesch S, Egger K (2013) Radial diffusivity in the cerebellar peduncles correlates with clinical severity in Friedreich ataxia. Neurol Sci 34(8):1459–1462
pubmed: 23640016
doi: 10.1007/s10072-013-1402-0
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P (2013) Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem 126(1):103–117
pubmed: 23859346
doi: 10.1111/jnc.12317
Armani M, Zortea M, Pastorello E, Lombardi S, Tonello S, Zuliani L, Rigoni MT, Trevisan CP (2006) Friedreich’s ataxia: clinical heterogeneity in two sisters. Neurol Sci 27(2):140–142
pubmed: 16816915
doi: 10.1007/s10072-006-0617-8
Bürk K, Mälzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hübsch T, Hering S, Lindig TM, Haug V, Timmann D, Degen I (2009) Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 24(12):1779–1784
pubmed: 19562766
doi: 10.1002/mds.22660
Bürk K, Schulz SR, Schulz JB (2013) Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem 126(1):18–124
Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717–1720
pubmed: 16769946
doi: 10.1212/01.wnl.0000219042.60538.92
Saute JAM, Donis KC et al (2012) Ataxia rating scales-psychometric profiles, natural history and their application in clinical trials. Cerebellum 11(2):488–504
pubmed: 21964941
doi: 10.1007/s12311-011-0316-8
Schmitz-Hübsch T, Fimmers R, Rakowicz M, Rola R, Zdzienicka E, Fancellu R et al (2010) Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74:678–684
pubmed: 20177122
pmcid: 20177122
doi: 10.1212/WNL.0b013e3181d1a6c9
Schmitz-Hübsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Saccà F et al (2008) SCA Functional Index - usefulness of a compound performance measure in spinocerebellar ataxia patients. Neurology. 71:486–492
pubmed: 18695159
doi: 10.1212/01.wnl.0000324863.76290.19
Du Montcel S, Charles P, Ribai P (2008) Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 131:1352–1361
pubmed: 18378516
pmcid: 18378516
doi: 10.1093/brain/awn059
Mathiowetz V, Weber K, Kashman N, Volland G (1985) Adult norms for the Nine Hole Peg Test of finger dexterity. Occup Ther J Res 5(1):24–38
doi: 10.1177/153944928500500102
Oxford Grice K, Vogel KA, Le V, Mitchell A, Muniz S, Vollmer MA (2003) Adult norms for a commercially available Nine Hole Peg Test for finger dexterity. Am J Occup Ther 57(5):570–573
pubmed: 14527120
doi: 10.5014/ajot.57.5.570
Saccà F et al (2016) Long-term effect of epoetin alfa on clinical and biochemical markers in Friedreich ataxia. Mov Disord 31:734–741
pubmed: 26879839
doi: 10.1002/mds.26552
Patel M et al (2019) Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia. Muscle Nerve 60(5):571–575
pubmed: 31206761
doi: 10.1002/mus.26610
Pandolfo M et al (2014) Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol 76:509–521
pubmed: 25112865
doi: 10.1002/ana.24248
Corben LA et al (2010) A comparison of three measures of upper limb function in Friedreich ataxia. J Neurol 257:518–523
pubmed: 19823893
doi: 10.1007/s00415-009-5352-7
Tai G et al (2017) How does performance of the Friedreich Ataxia Functional Composite compare to rating scales? J Neurol 264:1768–1776
pubmed: 28695363
doi: 10.1007/s00415-017-8566-0
Arcuria G, Marcotulli C, Galasso C, Pierelli F, Casali C (2019) 15-White Dots APP-Coo-Test: a reliable touch-screen application for assessing upper limb movement impairment in patients with cerebellar ataxias. J Neurol 266(7):1611–1622
pubmed: 30955123
doi: 10.1007/s00415-019-09299-9
Solari A, Radice D, Manneschi L et al (2005) The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 228:71–74
pubmed: 15607213
doi: 10.1016/j.jns.2004.09.033
Serrao M, Pierelli F, Ranavolo A, Draicchio F, Conte C, Casali C et al (2012) Gait pattern in inherited cerebellar ataxias. Cerebellum 11(1):194–211
pubmed: 21717229
doi: 10.1007/s12311-011-0296-8
Portney LG, Watkins MP (2009) Foundations of clinical research: applications to practice, 3rd edn. Prentice Hall, Upper Saddle River
Harvill L (1991) Standard error of measurement. Educ Meas 10:33–41
doi: 10.1111/j.1745-3992.1991.tb00195.x
Donoghue D, Stokes EK (2009) How much change is true change? The minimum detectable change of the Berg Balance Scale in elderly people. J Rehabil Med 41:343–346
pubmed: 19363567
doi: 10.2340/16501977-0337
Haley SM, Fragala-Pinkham MA (2006) Interpreting change scores of tests and measures used in physical therapy. Phys Ther 86:735–743
pubmed: 16649896
doi: 10.1093/ptj/86.5.735
Long A, Napierala JS, Polak U, Hauser L, Koeppen AH, Lynch DR et al (2017) Somatic instability of the expanded GAA repeats in Friedreich’s ataxia. PLoS One 12(12):e0189990
pubmed: 29261783
pmcid: 5736210
doi: 10.1371/journal.pone.0189990
De Biase I, Rasmussen A, Endres D, Al-Mahdawi S, Monticelli A, Cocozza S (2007) Progressive GAA expansions in dorsal root ganglia of Friedreich’s ataxia patients. Ann Neurol 61:55–60
pubmed: 17262846
doi: 10.1002/ana.21052
Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, Cocozza S (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59(3):554–560
pubmed: 8751856
pmcid: 1914893